Analysts Set Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Price Target at $215.38

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have received an average recommendation of “Moderate Buy” from the sixteen research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $215.3846.

JAZZ has been the topic of several research reports. Royal Bank Of Canada upped their price objective on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Needham & Company LLC raised their target price on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Truist Financial raised Jazz Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Friday. Finally, Bank of America raised their price objective on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $189.05 on Friday. The stock has a market capitalization of $11.64 billion, a price-to-earnings ratio of -31.67, a PEG ratio of 0.33 and a beta of 0.22. Jazz Pharmaceuticals has a 52-week low of $95.49 and a 52-week high of $198.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86. The stock’s 50 day moving average price is $176.33 and its two-hundred day moving average price is $161.11.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, beating the consensus estimate of $6.49 by $0.15. The company had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. Jazz Pharmaceuticals’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.51 EPS. On average, equities analysts predict that Jazz Pharmaceuticals will post 16.96 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 55,600 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $191.56, for a total value of $10,650,736.00. Following the completion of the sale, the executive vice president owned 56,862 shares of the company’s stock, valued at approximately $10,892,484.72. This trade represents a 49.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Norbert G. Riedel sold 3,415 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $192.00, for a total transaction of $655,680.00. Following the sale, the director owned 7,024 shares of the company’s stock, valued at $1,348,608. This trade represents a 32.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 68,015 shares of company stock valued at $13,037,486 in the last 90 days. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several large investors have recently added to or reduced their stakes in JAZZ. Dimensional Fund Advisors LP increased its holdings in Jazz Pharmaceuticals by 11.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after purchasing an additional 298,815 shares in the last quarter. Capital World Investors lifted its holdings in shares of Jazz Pharmaceuticals by 4.4% in the fourth quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock valued at $453,322,000 after purchasing an additional 111,735 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 11.4% in the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after purchasing an additional 191,637 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Jazz Pharmaceuticals by 8.5% during the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after buying an additional 145,865 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Jazz Pharmaceuticals by 164.0% during the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after buying an additional 1,129,995 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.